Skip to main content
SpringerLink
Log in

Inflammatory Breast Cancer: Chemotherapy of Metastatic Disease

  • Chapter
  • First Online:
Inflammatory Breast Cancer: An Update

  • 795 Accesses

Abstract

Metastatic disease is frequently observed in inflammatory breast cancer (IBC). IBC with synchronous metastases are generally treated similarly to non-metastatic disease, including optimal primary systemic treatment and, in case of favorable response, appropriate loco-regional treatment. Although evidences accumulate for considering IBC as a unique clinical, pathological and molecular entity, current treatment of secondary metastatic IBC follows the general recommendation of metastatic breast cancer management. Metastatic breast cancer (MBC) is considered to be incurable, but has a highly heterogeneous outcome. Quality of life and patient choices are important parameters in therapeutic decision. Specific treatment is based on standard molecular typing including ER, PR and HER2 expression. Chemotherapy is the major therapeutic option for hormone-insensitive and/or rapidly growing inflammatory MBC. Main classes of therapeutic compounds remains anthracyclines and taxanes. Issues such as monochemotherapy vs. polychemotherapy, optimal duration, optimal schedule of administration, place of high-dose chemotherapy are not clearly solved. Anti-metabolites, such as gemcitabine and capecitabine, as well as various antimicrotubules agents (vinorelbine and the most recently registered compounds ixabepilone and eribulin) may be used in anthracyclines and/or taxane-resistant disease. Cytotoxics must be combined to anti-HER-2 agents (such as trastuzumab or lapatinib) in HER2-positive inflammatory MBC, whereas the impact of adding bevacizumab to chemotherapy in HER2-negative disease was recently challenged. Development of specific, molecularly-driven, clinical trials is warranted for inflammatory MBC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Cristofanilli M, Valero V, Buzdar AU et al (2007) Inflammatory breast cancer (IBC) and patterns of recurrence. Cancer 110:1436–1444

    Article  PubMed  Google Scholar 

  2. Hance KW, Anderson WF, Devesa SS et al (2005) Trends in inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results program at the National Cancer Institute. J Natl Cancer Inst 97:966–975

    Article  PubMed  Google Scholar 

  3. Dawood S, Ueno NT, Valero V et al (2011) Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer 117(9):1819–1826

    Article  PubMed  Google Scholar 

  4. Sutherland S, Ashley S, Walsh G et al (2010) Inflammatory breast cancer – the Royal Marsden Hospital experience: a review of 155 patients treated from 1990 to 2007. Cancer 116:2815–2820

    Article  PubMed  Google Scholar 

  5. Robertson FM, Bondy M, Yang W et al (2010) Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin 60:351–375

    Article  PubMed  Google Scholar 

  6. Chia SK, Speers CH, D’Yachkova Y et al (2007) The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 110:973–979

    Article  PubMed  Google Scholar 

  7. Mauri D, Polyzos NP, Salanti G et al (2008) Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J Natl Cancer Inst 100:1780–1791

    Article  PubMed  CAS  Google Scholar 

  8. Gennari A, Conte P, Nanni O et al (2005) Multicenter randomised trial of paclitaxel (P) maintenance chemotherapy (CT) vs. control in metastatic breast cancer (MBC) patients achieving a response or stable disease to first-line CT including anthracyclines and paclitaxel: final results from the Italian MANTA study. J Clin Oncol (Meeting Abstracts) 23:522

    Google Scholar 

  9. Dawood S, Broglio K, Buzdar AU et al (2010) Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 28:92–98

    Article  PubMed  CAS  Google Scholar 

  10. Orlando L, Colleoni M, Fedele P et al (2007) Management of advanced breast cancer. Ann Oncol 18(Suppl 6):vi74–vi76

    Article  PubMed  Google Scholar 

  11. Guarneri V, Giovannelli S, Ficarra G et al (2008) Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. Oncologist 13:838–844

    Article  PubMed  CAS  Google Scholar 

  12. Curigliano G, Bagnardi V, Viale G et al (2011) Should liver metastases of breast cancer be biopsied to improve treatment choice? Ann Oncol. doi:10.1093/annonc/mdq751

  13. Simmons C, Miller N, Geddie W et al (2009) Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol 20:1499–1504

    Article  PubMed  CAS  Google Scholar 

  14. Cristofanilli M, Budd GT, Ellis MJ et al (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Eng J Med 351:781–791

    Article  CAS  Google Scholar 

  15. Dawood S, Broglio K, Buzdar AU et al (2009) Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 28:92–98

    Article  PubMed  Google Scholar 

  16. Parton M, Dowsett M, Ashley S et al (2004) High incidence of HER-2 positivity in inflammatory breast cancer. Breast 13:97–103

    Article  PubMed  CAS  Google Scholar 

  17. Sawaki M, Ito Y, Akiyama F et al (2006) High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer. Breast Cancer 13:172–178

    Article  PubMed  Google Scholar 

  18. Kleer C, van Golen K, Merajver S (2000) Molecular biology of breast metastasis: inflammatory breast cancer - clinical syndrome and molecular determinants. Breast Cancer Res 2:423–429

    Article  PubMed  CAS  Google Scholar 

  19. Gilabert M, Bertucci F, Esterni B et al (2011) Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors. Anticancer Res 31:1079–1086

    PubMed  CAS  Google Scholar 

  20. Goncalves A, Deblock M, Esterni B et al (2009) Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status. Anticancer Drugs 20:946–952

    Article  PubMed  CAS  Google Scholar 

  21. Johnston S, Pippen J Jr, Pivot X et al (2009) Lapatinib combined with letrozole vs. letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27:5538–5546

    Article  PubMed  CAS  Google Scholar 

  22. Kaufman B, Mackey JR, Clemens MR et al (2009) Trastuzumab plus anastrozole vs. anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 27:5529–5537

    Article  PubMed  CAS  Google Scholar 

  23. Chan S, Friedrichs K, Noel D et al (1999) Prospective randomized trial of docetaxel vs. doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17:2341–2354

    PubMed  CAS  Google Scholar 

  24. Sledge GW, Neuberg D, Bernardo P et al (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21:588–592

    Article  PubMed  Google Scholar 

  25. Paridaens R, Biganzoli L, Bruning P et al (2000) Paclitaxel vs. doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European organization for research and treatment of cancer randomized study with cross-over. J Clin Oncol 18:724–733

    PubMed  CAS  Google Scholar 

  26. Verrill MW, Lee J, Cameron DA et al (2007) Anglo-Celtic IV: first results of a UK National Cancer Research Network randomized phase III pharmacogenetic trial of weekly compared to 3 weekly paclitaxel in patients with locally advanced or metastatic breast cancer (ABC). J Clin Oncol (Meeting Abstracts) 25:LBA1005

    Google Scholar 

  27. Seidman AD, Berry D, Cirrincione C et al (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of cancer and leukemia group B protocol 9840. J Clin Oncol 26:1642–1649

    Article  PubMed  CAS  Google Scholar 

  28. Mauri D, Kamposioras K, Tsali L et al (2010) Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: a meta-analysis. Cancer Treat Rev 36:69–74

    Article  PubMed  CAS  Google Scholar 

  29. Jassem J, Pienkowski T, Pluzanska A et al (2001) Doxorubicin and paclitaxel vs. fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 19:1707–1715

    PubMed  CAS  Google Scholar 

  30. Langley RE, Carmichael J, Jones AL et al (2005) Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01. J Clin Oncol 23:8322–8330

    Article  PubMed  CAS  Google Scholar 

  31. Biganzoli L, Cufer T, Bruning P et al (2002) Doxorubicin and paclitaxel vs. doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European organization for research and treatment of cancer 10961 multicenter phase III trial. J Clin Oncol 20:3114–3121

    Article  PubMed  CAS  Google Scholar 

  32. Nabholtz JM, Falkson C, Campos D et al (2003) Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 21:968–975

    Article  PubMed  CAS  Google Scholar 

  33. Bontenbal M, Creemers GJ, Braun HJ et al (2005) Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch community setting trial for the clinical trial group of the comprehensive Cancer centre. J Clin Oncol 23:7081–7088

    Article  PubMed  CAS  Google Scholar 

  34. Bonneterre J, Dieras V, Tubiana-Hulin M et al (2004) Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. Br J Cancer 91:1466–1471

    PubMed  CAS  Google Scholar 

  35. Piccart-Gebhart MJ, Burzykowski T, Buyse M et al (2008) Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol 26:1980–1986

    Article  PubMed  CAS  Google Scholar 

  36. O’Brien ME, Wigler N, Inbar M et al (2004) Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) vs. conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15:440–449

    Article  PubMed  Google Scholar 

  37. Batist G, Ramakrishnan G, Rao CS et al (2001) Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 19:1444–1454

    PubMed  CAS  Google Scholar 

  38. Ravdin PM, Burris HA 3rd, Cook G et al (1995) Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13:2879–2885

    PubMed  CAS  Google Scholar 

  39. Valero V, Holmes FA, Walters RS et al (1995) Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13:2886–2894

    PubMed  CAS  Google Scholar 

  40. Sjostrom J, Blomqvist C, Mouridsen H et al (1999) Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 35:1194–1201

    Article  PubMed  CAS  Google Scholar 

  41. Nabholtz JM, Senn HJ, Bezwoda WR et al (1999) Prospective randomized trial of docetaxel vs. mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 study group. J Clin Oncol 17:1413–1424

    PubMed  CAS  Google Scholar 

  42. Jones SE, Erban J, Overmoyer B et al (2005) Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23:5542–5551

    Article  PubMed  CAS  Google Scholar 

  43. Gradishar WJ, Tjulandin S, Davidson N et al (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794–7803

    Article  PubMed  CAS  Google Scholar 

  44. Gradishar WJ, Krasnojon D, Cheporov S et al (2009) Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 27:3611–3619

    Article  PubMed  CAS  Google Scholar 

  45. O’Shaughnessy J, Miles D, Vukelja S et al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812–2823

    Article  PubMed  Google Scholar 

  46. Albain KS, Nag SM, Calderillo-Ruiz G et al (2008) Gemcitabine plus paclitaxel vs. paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 26:3950–3957

    Article  PubMed  Google Scholar 

  47. Chan S, Romieu G, Huober J et al (2009) Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol 27:1753–1760

    Article  PubMed  CAS  Google Scholar 

  48. Beslija S, Obralic N, Basic H et al (2006) Randomized trial of sequence vs. combination of capecitabine (X) and docetaxel (T): XT vs. T followed by X after progression as first-line therapy for patients (pts) with metastatic breast cancer (MBC). J Clin Oncol (Meeting Abstracts) 24:571

    Google Scholar 

  49. Soto C, Torrecillas L, Reyes S et al (2006) Capecitabine (X) and taxanes in patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): sequential vs. combined therapy results from a MOSG randomized phase III trial. J Clin Oncol (Meeting Abstracts) 24:570

    Google Scholar 

  50. Gennari A, Bruzzi P, Orlandini C et al (2004) Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy. Br J Cancer 90:962–967

    Article  PubMed  CAS  Google Scholar 

  51. Venturini M, Bruzzi P, Del Mastro L et al (1996) Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer. J Clin Oncol 14:764–773

    PubMed  CAS  Google Scholar 

  52. Pacilio C, Morabito A, Nuzzo F et al (2006) Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial. Br J Cancer 94:1233–1236

    Article  PubMed  CAS  Google Scholar 

  53. Bachelot T, Luporsi E, Bajard A et al (2008) Randomized trial of first-line docetaxel + capecitabine (XT) vs. docetaxel + epirubicin (ET) for metastatic breast cancer (MBC): efficacy results of ERASME-4/CAPEDOC-EPIDOC. J Clin Oncol (Meeting Abstracts) 26:1049

    Google Scholar 

  54. Blum JL, Jones SE, Buzdar AU et al (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485–493

    PubMed  CAS  Google Scholar 

  55. Blum JL, Dieras V, Lo Russo PM et al (2001) Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92:1759–1768

    Article  PubMed  CAS  Google Scholar 

  56. Reichardt P, Von Minckwitz G, Thuss-Patience PC et al (2003) Multicenter phase II study of oral capecitabine (Xeloda(″)) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 14:1227–1233

    Article  PubMed  CAS  Google Scholar 

  57. Fumoleau P, Largillier R, Clippe C et al (2004) Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 40:536–542

    Article  PubMed  CAS  Google Scholar 

  58. Wist EA, Sommer HH, Ostenstad B et al (2004) Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer. Acta Oncol 43:186–189

    Article  PubMed  Google Scholar 

  59. Degardin M, Bonneterre J, Hecquet B et al (1994) Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 5:423–426

    PubMed  CAS  Google Scholar 

  60. Heinemann V (2003) Role of gemcitabine in the treatment of advanced and metastatic breast cancer. Oncology 64:191–206

    Article  PubMed  CAS  Google Scholar 

  61. Rha SY, Moon YH, Jeung HC et al (2005) Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast Cancer Res Treat 90:215–221

    Article  PubMed  CAS  Google Scholar 

  62. Cortes J, Baselga J (2007) Targeting the microtubules in breast cancer beyond taxanes: the epothilones. Oncologist 12:271–280

    Article  PubMed  CAS  Google Scholar 

  63. Perez EA, Lerzo G, Pivot X et al (2007) Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 25:3407–3414

    Article  PubMed  CAS  Google Scholar 

  64. Thomas ES, Gomez HL, Li RK et al (2007) Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25:5210–5217

    Article  PubMed  CAS  Google Scholar 

  65. Jordan MA, Kamath K, Manna T et al (2005) The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 4:1086–1095

    Article  PubMed  CAS  Google Scholar 

  66. Cortes J, O’Shaughnessy J, Loesch D et al (2011) Eribulin monotherapy vs. treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377:914–923

    Article  PubMed  CAS  Google Scholar 

  67. Carrick S, Parker S, Thornton CE et al (2009) Single agent vs. combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2009:CD003372. doi:003310.001002/14651858.CD14003372.pub14651853

    Google Scholar 

  68. Nieto Y, Shpall EJ (2009) High-dose chemotherapy for high-risk primary and metastatic breast cancer: is another look warranted? Curr Opin Oncol 21:150–157

    Article  PubMed  CAS  Google Scholar 

  69. Miller KD, Chap LI, Holmes FA et al (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792–799

    Article  PubMed  CAS  Google Scholar 

  70. Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab vs. paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666–2676

    Article  PubMed  CAS  Google Scholar 

  71. Miles DW, Chan A, Dirix LY et al (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. doi:10.1200/JCO.2008.21.6457

  72. Robert NJ, Dieras V, Glaspy J et al (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29:1252–1260

    Article  PubMed  CAS  Google Scholar 

  73. Baselga J, Tripathy D, Mendelsohn J et al (1996) Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737–744

    PubMed  CAS  Google Scholar 

  74. Cobleigh MA, Vogel CL, Tripathy D et al (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639–2648

    PubMed  CAS  Google Scholar 

  75. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792

    Article  PubMed  CAS  Google Scholar 

  76. Marty M, Cognetti F, Maraninchi D et al (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23:4265–4274

    Article  PubMed  CAS  Google Scholar 

  77. Gasparini G, Gion M, Mariani L et al (2007) Randomized phase II trial of weekly paclitaxel alone vs. trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast Cancer Res Treat 101:355–365

    Article  PubMed  CAS  Google Scholar 

  78. Robert N, Leyland-Jones B, Asmar L et al (2006) Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24:2786–2792

    Article  PubMed  CAS  Google Scholar 

  79. Valero V, Forbes J, Pegram MD et al (2011) Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol 29:149–156

    Article  PubMed  CAS  Google Scholar 

  80. Wardley AM, Pivot X, Morales-Vasquez F et al (2010) Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. J Clin Oncol 28:976–983

    Article  PubMed  CAS  Google Scholar 

  81. Jahanzeb M, Mortimer JE, Yunus F et al (2002) Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer. Oncologist 7:410–417

    Article  PubMed  CAS  Google Scholar 

  82. Burstein HJ, Harris LN, Marcom PK et al (2003) Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 21:2889–2895

    Article  PubMed  CAS  Google Scholar 

  83. Chan A, Martin M, Untch M et al (2006) Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial. Br J Cancer 95:788–793

    Article  PubMed  CAS  Google Scholar 

  84. O’Shaughnessy JA, Vukelja S, Marsland T et al (2004) Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin Breast Cancer 5:142–147

    Article  PubMed  Google Scholar 

  85. O’Shaughnessy J (2003) Gemcitabine and trastuzumab in metastatic breast cancer. Semin Oncol 30:22–26

    PubMed  Google Scholar 

  86. Bartsch R, Wenzel C, Altorjai G et al (2007) Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 25:3853–3858

    Article  PubMed  CAS  Google Scholar 

  87. Schaller G, Fuchs I, Gonsch T et al (2007) Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol 25:3246–3250

    Article  PubMed  CAS  Google Scholar 

  88. Andersson M, Lidbrink E, Bjerre K et al (2011) Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol 29:264–271

    Article  PubMed  CAS  Google Scholar 

  89. Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743

    Article  PubMed  CAS  Google Scholar 

  90. von Minckwitz G, du Bois A, Schmidt M et al (2009) Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03–05 study. J Clin Oncol 27:1999–2006

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Département d’Oncologie Médicale, Institut Paoli-Calmettes, 232 Bd Sainte-Marguerite, 13009, Marseille, France

    Anthony Gonçalves & Patrice Viens

  2. Centre de Recherche en Cancérologie de Marseille, U1068 INSERM, UMR7258 CNRS, Aix-Marseille Université, Marseille, France

    Anthony Gonçalves & Patrice Viens

Authors
  1. Anthony Gonçalves
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patrice Viens
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrice Viens .

Editor information

Editors and Affiliations

  1. MD Anderson Cancer Center, Dept. Breast Medical Oncology, University of Texas, Holcombe Blvd. 1515, Houston, 77030-4095, Texas, USA

    Naoto T. Ueno

  2. Fox Chase Cancer Center, Cottman Avenue; Room C315 333, Philadelphia, 19111, Pennsylvania, USA

    Massimo Cristofanilli

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media B.V.

About this chapter

Cite this chapter

Gonçalves, A., Viens, P. (2012). Inflammatory Breast Cancer: Chemotherapy of Metastatic Disease. In: Ueno, N., Cristofanilli, M. (eds) Inflammatory Breast Cancer: An Update. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-3907-9_10

Download citation

Publish with us

Policies and ethics

Search

Navigation